focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Corrected: Roche is not moving forward with SQZ, sending the biotech into strategic review
Lei Lei Wu
News Reporter
This story was corrected to note that Roche has elected not to take its option on SQZ’s program. A previous version said that Roche and SQZ had ended their partnership.
Roche is walking away from its collaboration on SQZ Biotechnologies’ clinical program.
Roche decided not to license and develop SQZ’s antigen presenting cells (APCs) that are designed to spark killer T cells to go after HPV16-positive cancers, the biotech announced Tuesday morning. The program is SQZ’s only APC in the clinic, which it is testing in a Phase I/II study in patients with head and neck, cervical, anal, vulvar, or penile cancers.
Just seen on chart 8.75p on 17/7/23.
Still a few of my other boats are cumming in .
Better if I had put money in Eli Lilly: results of Alzheimer's study.
There good news all over TV last 3 days .
But share price was higher last week , share price moving on such a good news RNS ?
The two hedge funds control the price here.
Redmile Group, LLC ,
Vulpes Investment Management Private Limited
"Why are the little little ramp group not buying when they mocked me for doubting the trish stuff and warning others .
Its right there in the RNS you utter clown
"One head and neck patient achieved a partial response and remains on study at week 37"
Bought again for 10.5p on an order for an 11p buy.
Down 20% by midday .
All shares on AIM just a gamble IMO.
Not cheap at 13p with today's hindsight .
13% drop today to 11p on the bid . spread 4.55%.
No news.
Look up boiler room groups.
Bought more today at 13p order executed immediately could of set a littler lower in hindsight .
Why are the little little ramp group not buying when they mocked me for doubting the trish stuff and warning others .
And abuse when I took some funds off the table .
Names easy to find on this thread , they do not get that is the point , maybe a couple do and they have my posts removed .
IMO take a note and ignore them all. .
Could have been 70 quid cheaper?
Congratulations, you bought them £17 cheaper in those 5 weeks.
Ripley,
Of what relevance is a thread title from two months ago? None.
It is rather misleading. I hope your purchase wasn’t based on the sentiment.
Bought more today at 14p on 14.2 buy order .
My post on 15/5/23 a buy at 15.5p removed , a little ramp group seem to be able to get that done .
Yawn.
Bought the last tranche sale back for 16.5p this morning .
After selling a tranche on 13/4/23 for 20p I posted within the hour , an article from February 2021 when there had been a sudden and aggressive buying of the stock that morning.
It had spiked to 27.5p rather like start of the the now removed thread that I posted it on last week .
Motley Fool had a view around the time the "What incredible news for Trish" posting was going on .
The ramppers maybe rinse and repeat after 2 years hoping readers of sites like this would not remember .
Maybe they had a joint effort to have that thread removed , they would not want me bringing up there posting history lol
This can be a costly site to read .
Double yawn
*repeatedly bring up the same topic, then find it boring when people reply on that topic*
yawn
"I honestly do not know which are in the gang and which are the sheepy ."
Have you considered that it might all just be made up in your head?
what's that got to do with it?
I get why some do not want old conversations pulled up .
KonarA 24/3/23.
"This isn't about bullying, or groups or individuals or even content... its just common message board ettiqute. You are posting all of your comments under the same thread which pulls old conversations to the top of the board."
oh ok, so now i get it - you invested on the say so of someone on here.. and lost a bunch of money you couldn't afford. Now you are bitter for not doing your own research and want to blame everyone else?
Motley Fool had a view around the time this "What incredible news for Trish" posting was going on .
It might be of interest to genuine investors to note the names , the gang want to divert away from there posts around this time of course .
Fact is you would of been better reading Motley and putting all the names who claimed Motley did not more then them on filter . ( and Motley sets a low bar )
SCLP is now half the price , the gang were probably selling as they ramped and the sheepy pi bark up the wrong tree as they suffer there losses .
These guys have no empathy, more dishonest then street muggers .
"The Motley Fool pieces these days could almost be written by robots……"
I'm pretty sure these are automated pieces, written whenever a stock makes X % over a given time period. Looks like it just scrapes generic info about a company and cobbles it together.
I wouldn't pay motley fool any attention anyway, pretty useless.